Works about SUNITINIB
Results: 262
Investigating Drug-Induced Thyroid Dysfunction Adverse Events Associated With Non-Selective RET Multi-Kinase Inhibitors: A Pharmacovigilance Analysis Utilizing FDA Adverse Event Reporting System Data.
- Published in:
- Clinical Epidemiology, 2025, v. 17, p. 87, doi. 10.2147/CLEP.S494215
- By:
- Publication type:
- Article
PDIA4 在肾癌细胞舒尼替尼耐药中的作用研究.
- Published in:
- Progress in Modern Biomedicine, 2024, v. 24, n. 13, p. 2408, doi. 10.13241/j.cnki.pmb.2024.13.002
- By:
- Publication type:
- Article
Pharmacovigilance imbalance analysis of VEGFR-TKI-related taste and smell disorders.
- Published in:
- Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-87678-1
- By:
- Publication type:
- Article
In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 6, p. 973, doi. 10.3390/biom13060973
- By:
- Publication type:
- Article
Functional Evaluation and Nephrotoxicity Assessment of Human Renal Proximal Tubule Cells on a Chip.
- Published in:
- Biosensors (2079-6374), 2022, v. 12, n. 9, p. 718, doi. 10.3390/bios12090718
- By:
- Publication type:
- Article
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy: Traditional Versus Pharmacometric Pharmacoeconomic Models for Cost-Utility Analysis of Sunitinib: M. Centanni et al
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 1, p. 31, doi. 10.1007/s40273-024-01438-z
- By:
- Publication type:
- Article
Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma.
- Published in:
- Cellular Oncology (2211-3428), 2024, v. 47, n. 4, p. 1277, doi. 10.1007/s13402-024-00927-9
- By:
- Publication type:
- Article
Exploration of the immune microenvironment of breast cancer in large population cohorts.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.955630
- By:
- Publication type:
- Article
N<sup>6</sup>-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma.
- Published in:
- Molecular Cancer, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12943-022-01549-1
- By:
- Publication type:
- Article
Vascular density and expression of vascular endothelial growth factor and angiopoietin‑1 using immunofluorescence technique in patients with metastatic renal cell carcinoma treated with first‑line sunitinib.
- Published in:
- Journal of Cancer Research & Therapeutics, 2023, v. 19, n. 2, p. 520, doi. 10.4103/jcrt.jcrt_256_22
- By:
- Publication type:
- Article
Sunitinib‑induced small bowel wall edema as a prognostic marker in metastatic renal cell carcinoma.
- Published in:
- Journal of Cancer Research & Therapeutics, 2023, v. 19, n. 2, p. 389, doi. 10.4103/jcrt.jcrt_899_21
- By:
- Publication type:
- Article
Identification Biomarkers and Molecular Mechanisms Involved in Lung Transplant Rejection, and Drug Repurposing: A Systems Biology Study.
- Published in:
- Journal of Advances in Medical & Biomedical Research, 2023, v. 31, n. 149, p. 525, doi. 10.30699/jambs.31.149.525
- By:
- Publication type:
- Article
Advanced renal cancer as a chronic disease — long-term disease control with a tyrosine kinase inhibitor (TKI) inhibitor.
- Published in:
- Nowotwory, 2024, v. 74, n. 5, p. 337, doi. 10.5603/njo.101194
- By:
- Publication type:
- Article
Outcomes of treatment, laboratory results, adverse effects, and tolerability of cancer treatment in patients with metastatic renal-cell carcinoma treated with sunitinib after cytoreductive nephrectomy.
- Published in:
- Nowotwory, 2024, v. 74, n. 2, p. 105, doi. 10.5603/njo.98971
- By:
- Publication type:
- Article
Clinical Significance and Expression Pattern of RIP5 and VGLL4 in Clear Cell Renal Cell Carcinoma Patients Treated with Sunitinib.
- Published in:
- Biomedicines, 2024, v. 12, n. 1, p. 149, doi. 10.3390/biomedicines12010149
- By:
- Publication type:
- Article
Catfish Egg Lectin Enhances the Cytotoxicity of Sunitinib on Gb3-Expressing Renal Cancer Cells.
- Published in:
- Biomedicines, 2023, v. 11, n. 8, p. 2317, doi. 10.3390/biomedicines11082317
- By:
- Publication type:
- Article
Whole Exome Sequencing Identifies PHF14 Mutations in Neurocytoma and Predicts Responsivity to the PDGFR Inhibitor Sunitinib.
- Published in:
- Biomedicines, 2022, v. 10, n. 11, p. 2842, doi. 10.3390/biomedicines10112842
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
- Published in:
- Biomedicines, 2022, v. 10, n. 3, p. 577, doi. 10.3390/biomedicines10030577
- By:
- Publication type:
- Article
Exploring the anti-metastatic potential of sunitinib and novel analogs in colorectal cancer: insights into HIF-1α mediated metastasis.
- Published in:
- Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1520881
- By:
- Publication type:
- Article
Osteonecrosis of the jaw in patients with clear cell renal cell carcinoma treated with targeted agents: a case series and large-scale pharmacovigilance analysis.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1309148
- By:
- Publication type:
- Article
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1407709
- By:
- Publication type:
- Article
Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib are Synergistically Dystrophic.
- Published in:
- Dicle Medical Journal / Dicle Tip Dergisi, 2022, v. 49, n. 3, p. 414, doi. 10.5798/dicletip.1170070
- By:
- Publication type:
- Article
Expressions of miR-96-5p, miR-29b-3p, and Their Target Gene THBS1 in Clear Cell Renal Cell Carcinoma and Sunitinib Resistance.
- Published in:
- Alternative Therapies in Health & Medicine, 2024, v. 30, n. 7, p. 268
- By:
- Publication type:
- Article
Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy.
- Published in:
- Livers, 2023, v. 3, n. 1, p. 121, doi. 10.3390/livers3010011
- By:
- Publication type:
- Article
基于PD-1/PD-L1 抑制剂联合疗法对比舒尼替尼治疗晚期肾细胞癌安全 性和有效性的Meta分析
- Published in:
- Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 5, p. 393, doi. 10.3872/j.issn.1007-385x.2023.05.005
- By:
- Publication type:
- Article
Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 22, p. 21041, doi. 10.1002/cam4.6663
- By:
- Publication type:
- Article
A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 12, p. 13100, doi. 10.1002/cam4.5990
- By:
- Publication type:
- Article
Efficacy of post‐first‐line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta‐analysis.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 11, p. 12187, doi. 10.1002/cam4.5912
- By:
- Publication type:
- Article
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 6, p. 6902, doi. 10.1002/cam4.5483
- By:
- Publication type:
- Article
Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 19, p. 3674, doi. 10.1002/cam4.4743
- By:
- Publication type:
- Article
Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 16, p. 3106, doi. 10.1002/cam4.4679
- By:
- Publication type:
- Article
Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-56335-4
- By:
- Publication type:
- Article
Apela promotes blood vessel regeneration and remodeling in zebrafish.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-023-50677-1
- By:
- Publication type:
- Article
Unveiling the Anti-Angiogenic Potential of Small-Molecule (Kinase) Inhibitors for Application in Rheumatoid Arthritis.
- Published in:
- Cells (2073-4409), 2025, v. 14, n. 2, p. 102, doi. 10.3390/cells14020102
- By:
- Publication type:
- Article
Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1294688
- By:
- Publication type:
- Article
Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1223929
- By:
- Publication type:
- Article
Preparation of a Sunitinib loaded microemulsion for ocular delivery and evaluation for the treatment of corneal neovascularization in vitro and in vivo.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1157084
- By:
- Publication type:
- Article
Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1209933
- By:
- Publication type:
- Article
The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.971142
- By:
- Publication type:
- Article
Comprehensive Analysis of Senescence Characteristics Defines a Novel Prognostic Signature to Guide Personalized Treatment for Clear Cell Renal Cell Carcinoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.901671
- By:
- Publication type:
- Article
Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome via Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis, and Sunitinib Sensitivity.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.842069
- By:
- Publication type:
- Article
Supplementary Materials.
- Published in:
- Frontiers in Endocrinology, 2024, p. 1
- Publication type:
- Article
Vogt-Koyanagi-Harada-Like Disease with Loss of Visual Acuity due to Sunitinib Treatment Restored after Switch in Therapy: A Case Report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Sunitinib Reduced the Migration of Ectopic Endometrial Cells via p-VEGFR-PI3K-AKT-YBX1-Snail Signaling Pathway.
- Published in:
- Analytical Cellular Pathology: Cellular Oncology, 2022, p. 1, doi. 10.1155/2022/6042518
- By:
- Publication type:
- Article
Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2023, v. 42, n. 1, p. 1, doi. 10.1186/s13046-023-02608-1
- By:
- Publication type:
- Article
YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02460-9
- By:
- Publication type:
- Article
YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02460-9
- By:
- Publication type:
- Article
Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects.
- Published in:
- PLoS ONE, 2024, v. 19, n. 6, p. 1, doi. 10.1371/journal.pone.0304782
- By:
- Publication type:
- Article
Importancia pronóstica de las mutaciones del gen promotor de la transcriptasa inversa de la telomerasa en los meningiomas de alto grado.
- Published in:
- Biomédica: Revista del Instituto Nacional de Salud, 2022, v. 42, n. 4, p. 574, doi. 10.7705/biomedica.6100
- By:
- Publication type:
- Article
The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
- Published in:
- Computational & Mathematical Methods in Medicine, 2022, p. 1, doi. 10.1155/2022/7341294
- By:
- Publication type:
- Article